RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.
|First Received Date||September 13, 2001|
|Last Changed Date||October 28, 2015|
|Start Date||May 2000|
|Actual Primary Completion Date||December 2006|
|Study Arms / Comparison Groups||1 / 0|
- Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
- Determine the efficacy of this treatment, in terms of local control, in these patients.
- Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.
OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.
Patients are followed at 1, 3, 6, and 12 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
|Ages||N/A - N/A|
|Accepts Healthy Volunteers||No|
- Diagnosis of a primary or secondary intrathoracic malignancy
- Any cell type or origin
- Involving the intrapulmonary, mediastinal, or pleural/chest wall
- Inoperable primary or metastatic cancer to the lung
- Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
- Single or multiple lesions that are non-contiguous with vital structures or organs such as:
- Great vessels
- Less than 5 cm in largest dimension
- Accessible via percutaneous transthoracic route
- Coagulation profile normal
|Sponsor||Jonsson Comprehensive Cancer Center|
|Verification Date||July 2012|